Precision Medicine

A novel staple-like device from Inovedis gains expanded FDA approval, promising faster, less invasive repairs for a vast range of orthopedic injuries.

A new AI-driven platform moves beyond static reports, offering continuous genomic updates to give cancer patients access to the latest treatment options.

A new alliance between UltraGreen and LifeSignals will bring advanced wearable heart monitors to a global market, tackling rising cardiovascular disease.

A new partnership aims to develop a diagnostic test for a hidden cancer biomarker, potentially unlocking a targeted therapy for patients with grim prognoses.

A breakthrough study in a Nature journal reveals a novel device, RefluxStop, has a stellar long-term safety record, offering hope for millions with severe GERD.

Following a breakthrough in chondrosarcoma, Inhibrx Biosciences is set to reveal pivotal data for its drug ozekibart in the vast colorectal cancer market.

Freshly spun-off from AnaptysBio, First Tracks Biotherapeutics hits the market with a strong cash position and a pipeline aimed at celiac disease and RA.

Upcoming Phase 1 data for ABCL635 could validate a novel antibody approach for hot flashes, challenging the market and offering new hope for millions.

Spurred by celebrity stories and a viral campaign, the Webby-winning Know Your Lemons app offers personalized risk scores and private screening plans.

A landmark conference merges top organizations to accelerate research on retinal diseases, from gene editing to AI, offering new hope for millions worldwide.

A groundbreaking knee implant offers Hoosiers a new joint-preserving option, bridging the gap between conservative care and total knee replacement.

A new alcohol-free, no-refrigeration blood pressure liquid aims to transform daily treatment for children, reflecting a key industry shift.

Astellas and Pfizer's PADCEV-Keytruda combo, showing a 47% drop in recurrence risk, earns FDA Priority Review, offering new hope for bladder cancer patients.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

New preclinical data reveals a novel drug, rinzimetostat, may overcome treatment resistance in prostate cancer by targeting a unique molecular switch.

A new gene therapy that reprograms cancer cells into immune activators shows major promise, blending personalized treatment with off-the-shelf convenience.

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

Interim study results suggest a common food product may significantly enhance the effectiveness of modern cancer treatments, heralding a new era of care.

A surprise $5 million pledge for glaucoma research highlights a gala honoring philanthropist Daria Barry, patient advocate Hillary Golden, and music icon Nile Rodgers.

New guidelines advise biennial screening for women 50-74 and caution for others, a move that has drawn sharp criticism from other medical bodies.